WO2024258949A3 - Nanoparticules d'immunosorbant et leurs procédés d'utilisation - Google Patents

Nanoparticules d'immunosorbant et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2024258949A3
WO2024258949A3 PCT/US2024/033583 US2024033583W WO2024258949A3 WO 2024258949 A3 WO2024258949 A3 WO 2024258949A3 US 2024033583 W US2024033583 W US 2024033583W WO 2024258949 A3 WO2024258949 A3 WO 2024258949A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunosorbent
nanoparticles
methods
microglobulin
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/033583
Other languages
English (en)
Other versions
WO2024258949A2 (fr
Inventor
Paul Moroz
Todd Yeates
Justin Miller
Roger CASTELLS-GRAELLS
Mark Aubrey ARBING
Aldo MUNOZ
Brian Thuan NGUYEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to AU2024303275A priority Critical patent/AU2024303275A1/en
Priority to EP24824061.6A priority patent/EP4727598A2/fr
Publication of WO2024258949A2 publication Critical patent/WO2024258949A2/fr
Publication of WO2024258949A3 publication Critical patent/WO2024258949A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des nanoparticules d'immunosorbant, des dispositifs et des procédés permettant l'élimination sélective d'une protéine cible telle que la bêta-2 microglobuline (B2M) à partir d'un liquide tel que le sang.
PCT/US2024/033583 2023-06-16 2024-06-12 Nanoparticules d'immunosorbant et leurs procédés d'utilisation Ceased WO2024258949A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2024303275A AU2024303275A1 (en) 2023-06-16 2024-06-12 Immunosorbent nanoparticles and methods of using thereof
EP24824061.6A EP4727598A2 (fr) 2023-06-16 2024-06-12 Nanoparticules d'immunosorbant et leurs procédés d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508514P 2023-06-16 2023-06-16
US63/508,514 2023-06-16

Publications (2)

Publication Number Publication Date
WO2024258949A2 WO2024258949A2 (fr) 2024-12-19
WO2024258949A3 true WO2024258949A3 (fr) 2025-02-13

Family

ID=93852878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033583 Ceased WO2024258949A2 (fr) 2023-06-16 2024-06-12 Nanoparticules d'immunosorbant et leurs procédés d'utilisation

Country Status (3)

Country Link
EP (1) EP4727598A2 (fr)
AU (1) AU2024303275A1 (fr)
WO (1) WO2024258949A2 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002278A1 (fr) * 1994-07-18 1996-02-01 Laboratoires Upsa Immunonanoparticules revetues d'anticorps monoclonaux anti-beta-2 microglobuline
US20110020311A1 (en) * 2009-07-27 2011-01-27 James Layne Boucher Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy
US20130118979A1 (en) * 2007-12-03 2013-05-16 Hepa Wash Gmbh Dialysate Regeneration Unit
US20150356240A1 (en) * 2013-02-07 2015-12-10 University of Washington Through it's Center for Commercialization Self-Assembling Protein Nanostructures
US20220062430A1 (en) * 2020-08-25 2022-03-03 The Regents Of The University Of California Self Assembling Protein Nanoparticles as Carrier Molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002278A1 (fr) * 1994-07-18 1996-02-01 Laboratoires Upsa Immunonanoparticules revetues d'anticorps monoclonaux anti-beta-2 microglobuline
US20130118979A1 (en) * 2007-12-03 2013-05-16 Hepa Wash Gmbh Dialysate Regeneration Unit
US20110020311A1 (en) * 2009-07-27 2011-01-27 James Layne Boucher Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy
US20150356240A1 (en) * 2013-02-07 2015-12-10 University of Washington Through it's Center for Commercialization Self-Assembling Protein Nanostructures
US20220062430A1 (en) * 2020-08-25 2022-03-03 The Regents Of The University Of California Self Assembling Protein Nanoparticles as Carrier Molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCNULTY MATTHEW J., SCHWARTZ ANTON, DELZIO JESSE, KARUPPANAN KALIMUTHU, JACOBSON AARON, HART OLIVIA, DANDEKAR ABHAYA, GIRITCH ANAT: "Affinity Sedimentation and Magnetic Separation With Plant-Made Immunosorbent Nanoparticles for Therapeutic Protein Purification", FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 10, CH , XP093280477, ISSN: 2296-4185, DOI: 10.3389/fbioe.2022.865481 *

Also Published As

Publication number Publication date
WO2024258949A2 (fr) 2024-12-19
EP4727598A2 (fr) 2026-04-22
AU2024303275A1 (en) 2026-01-15

Similar Documents

Publication Publication Date Title
WO2004113922A3 (fr) Systeme et procede mettant en oeuvre des techniques photocinetiques dans des applications d'imagerie de biologie cellulaire
SE0201317D0 (sv) Method and device for the removal of partially protein bound substances
WO2022175414A8 (fr) Anticorps multispécifiques anti-domaine delta 1 variable de tcr
EP4632066A3 (fr) Systèmes crispr de classe ii, type ii
WO2005000095A3 (fr) Isoformes pour peptide natriuretique du cerveau
WO2000059380A3 (fr) Dispositif et procedes pour effectuer une anastomose
TW200624173A (en) Process and apparatus for improved methods for making vinyl acetate monomer (vam)
NO975511L (no) Ikke-ioniske vandige polyuretandispersjoner og fremgangsmÕter for fremstilling
WO2024258949A3 (fr) Nanoparticules d'immunosorbant et leurs procédés d'utilisation
EP4273161A4 (fr) Protéine contenant un anticorps hétérodimère fc et son procédé de préparation
WO2005118885A3 (fr) Procedes et appareil de detection d'infections virales
WO2023146922A3 (fr) Procédés de typage et de phasage d'antigènes leucocytaires humains
WO2006039555A3 (fr) Dispositif et methode d'annihilation de l'hypotension
MX2008001861A (es) Sistema de desconexion de emergencia.
WO2021191674A3 (fr) Procédés de criblage d'un réactif anti-virus à l'aide d'organoïdes
EP4115446A4 (fr) Système, procédé, et cible d'alignement de tranche
WO2006106400A3 (fr) Capsules renfermant de la matiere seminale pour insemination artificielle
WO2022198052A3 (fr) Membrane de microémulsification haut débit
WO2004011401A3 (fr) Procede de fabrication de puces biologiques
WO2023196598A3 (fr) Anticorps anti-mica/b et leurs utilisations
GB2605887A (en) Controlled chemical synthesis using polymer substrates and nanofluidic separation systems
CA3297377A1 (fr) Anticorps anti-protéine a-beta, procédés et utilisations associés
NO20055948L (no) Rensing av HER-2 varianter
CA3286430A1 (fr) Procédés et réactifs pour synthétiser des haloaldéhydes, et leurs utilisations
NZ604943A (en) Modified protozoan expressing at least two variable surface proteins (vsp), a vaccine comprising it and procedures, uses, and methods thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: AU2024303275

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2024303275

Country of ref document: AU

Date of ref document: 20240612

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2024824061

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2024824061

Country of ref document: EP

Effective date: 20260116

ENP Entry into the national phase

Ref document number: 2024824061

Country of ref document: EP

Effective date: 20260116

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24824061

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2024824061

Country of ref document: EP